Medtronic Stock Soars After Analysts' Upgrade and FDA Approval.

Medtronic's stock received an upgrade from Wells Fargo, with analysts raising their target price to $100 and changing their rating to Overweight. The approval of Medtronic's 708G insulin delivery system in the US is seen as a "major milestone" and the company's pipeline of products is maturing, contributing to the positive outlook for the general medtech market.